Wall Street Analysts Think NeuroPace (NPCE) Could Surge 31.47%: Read This Before Placing a BetZacks Investment Research • 12/06/24
NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual MeetingGlobeNewsWire • 12/04/24
NeuroPace Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut SyndromeGlobeNewsWire • 12/03/24
Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 54.34%: Here's is How to TradeZacks Investment Research • 11/18/24
NeuroPace Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal EpilepsyGlobeNewsWire • 11/04/24
Strength Seen in NeuroPace (NPCE): Can Its 5.1% Jump Turn into More Strength?Zacks Investment Research • 10/28/24
NeuroPace to Report Third Quarter 2024 Financial Results on November 12, 2024GlobeNewsWire • 10/22/24
NeuroPace Announces Participation at Two Upcoming Healthcare Investor ConferencesGlobeNewsWire • 08/27/24
NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/08/24
NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024GlobeNewsWire • 02/15/24